Koumprentziotis IA, Tsiogka A, Kleidona IA, Vaiopoulos A, et al. Sustained Minimal Disease Activity With Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 104-Week, Real-World, Retrospective Study. Int J Dermatol 2026 Jun 25. doi: 10.1111/ijd.70558.
PMID: 42347758